CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue:
Total revenue	$ 8,691,424	$ 10,598,847
Cost of revenue	2,277,636	2,751,444
Gross margin	6,413,788	7,847,403
Other expenses:
Research and development	4,243,365	2,282,052
Legal, financial and other consulting	800,735	707,839
Selling, general and administrative	9,160,823	7,709,703
Total expenses	14,204,923	10,699,594
Loss from operations	(7,791,135)	(2,852,191)
Other income (expense):
Interest expense, net	8,027	(10,124)
Miscellaneous income	30,000
Loss on foreign currency transactions	(1,213,290)	(1,305,506)
Total other expense, net	(1,175,263)	(1,315,630)
Loss before benefit from income taxes	(8,966,398)	(4,167,821)
Benefit from income taxes	0	0
Net loss attributable to common stockholders	$ (8,966,398)	$ (4,167,821)
Basic net loss per common share	$ (0.21)	$ (0.10)
Diluted net loss per common share	$ (0.21)	$ (0.10)
Weighted average number of shares of common stock outstanding, basic	43,487,946	43,242,791
Weighted average number of shares of common stock outstanding, diluted	41,593,218	43,319,507
Comprehensive loss:
Net loss	$ (8,966,398)	$ (4,167,821)
Other comprehensive income:
Currency translation adjustment	962,911	1,157,736
Comprehensive loss	(8,003,487)	(3,010,085)
Product
Revenue:
Total revenue	7,924,457	10,143,356
Cyto Sorb Sales
Revenue:
Total revenue	7,866,865	10,143,356
Other product sales
Revenue:
Total revenue	57,592
Grant and other income
Revenue:
Total revenue	$ 766,967	$ 455,491